Journal
PHYTOCHEMISTRY REVIEWS
Volume 9, Issue 4, Pages 557-579Publisher
SPRINGER
DOI: 10.1007/s11101-010-9200-2
Keywords
Cancer; Marine plants; Natural products; Phytoplankton; Symbionts
Categories
Funding
- BBSRC
- European Union [215009]
- Recherches Scientifiques Luxembourg asbl
- Een Haerz fir Kriibskrank Kanner association
- Action Lions Vaincre le Cancer Luxembourg
- Fonds National de la Recherche Luxembourg, Televie Luxembourg
- Foundation for Scientific, Germany
- Foundation for Scientific, Luxemburg
- Fonds National de la Recherche-Luxembourg
Ask authors/readers for more resources
Since early human history, plants have served as the most important source of medicinal natural products, and even in the synthetic age the majority of lead compounds for pharmaceutical development remain of plant origin. In the marine realm, algae and seagrasses were amongst the first organisms investigated by marine natural products scientists on their quest for novel pharmaceutical compounds. Forty years after the pioneering work in the field of marine drug discovery began, the biodiversity of marine organisms investigated as potential sources of anticancer, anti-inflammatory, and antibiotic compounds has increased tremendously. Nonetheless, marine plants are still an important source of novel secondary metabolites with interesting biomedical properties. The present review focuses on the antitumour properties of compounds isolated from marine algae, phytoplankton, mangroves, seagrasses, or cordgrasses. Compounds produced by marine epi- or endophytic fungi are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available